Belimumab for systemic lupus erythematosus: breaking through?

被引：11

作者：

Dall'Era, Maria ^{[1
,2
]}

Wofsy, David ^{[1
,2
]}

机构：

[1] Univ Calif San Francisco, Rosalind Russell Med Res Ctr, San Francisco, CA 94143 USA

[2] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94143 USA

来源：

NATURE REVIEWS RHEUMATOLOGY | 2010年 / 6卷 / 03期

关键词：

D O I：

10.1038/nrrheum.2010.20

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Belimumab was recently shown to reduce disease activity in patients with systemic lupus erythematosus. This observation raises important questions about where belimumab might best fit into the treatment paradigm for this disease, and how the agent might compare to other biologic agents currently under investigation.

引用

页码：124 / 125

页数：3

共 6 条

[1] Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis [J].

Appel, Gerald B. ;

Contreras, Gabriel ;

Dooley, Mary Anne ;

Ginzler, Ellen M. ;

Isenberg, David ;

Jayne, David ;

Li, Lei-Shi ;

Mysler, Eduardo ;

Sanchez-Guerrero, Jorge ;

Solomons, Neil ;

Wofsy, David .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (05) :1103-1112

[2]

Furie R, 2009, ARTHRITIS RHEUM, V60, pS429

[3]

GlaxoSmithKline, 2009, GLAXOSMITHKLINE HUM

[4]

MERRILL JT, AM COLL RHEUM 2008 A

[5]

NAVARRA S, AM COLL RHEUM 2009 A

[6] A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus [J].

Wallace, Daniel J. ;

Stohl, William ;

Furie, Richard A. ;

Lisse, Jeffrey R. ;

McKay, James D. ;

Merrill, Joan T. ;

Petri, Michelle A. ;

Ginzler, Ellen M. ;

Chatham, W. Winn ;

McCune, W. Joseph ;

Fernandez, Vivian ;

Chevrier, Marc R. ;

Zhong, Z. John ;

Freimuth, William W. .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (09) :1168-1178

← 1 →